IDH1 and central nervous system cancer: The latest WHO classification of CNS tumors termed gliomas of WHO grades I–III together as “lower-grade gliomas” with a great majority of IDH1 mutations and a wide range of overall survival within this group (Cancer Genome Atlas Research Network et al., 2015; Louis et al., 2016).